CJC-1295 (No DAC) vs Oxytocin: Mechanism, Half-Life & Research Use

Direct Comparison: Core Differences at a Glance

CJC-1295 (No DAC) and oxytocin represent fundamentally distinct classes of synthetic research peptides. CJC-1295 (No DAC) is a 29-amino-acid growth hormone-releasing hormone (GHRH) analog engineered to stimulate pituitary somatotrophs, whereas oxytocin is a nonapeptide hypothalamic neurohormone targeting oxytocin receptors (OXTR) to modulate social behavior, smooth muscle tone, and neuroendocrine cascades in preclinical models.

While CJC-1295 (No DAC) is primarily investigated for its capacity to sustain pulsatile growth hormone (GH) release and elevate insulin-like growth factor 1 (IGF-1) in cellular and rodent models, oxytocin is evaluated for its role in central neurotransmission, autonomic regulation, and reproductive tissue dynamics. Consequently, laboratory design dictate which peptide is appropriate based on whether the target pathway involves metabolic/somatotropic activation or central neuroendocrine signaling.

Comparative Technical Specifications

To assist laboratory personnel in protocol development, the table below outlines the primary physicochemical and biological parameters differentiating these two compounds:

| Technical Parameter | CJC-1295 (No DAC) (Modified GRF 1-29) | Oxytocin | |---|---|---| | Mechanistic Class | Growth Hormone-Releasing Hormone (GHRH) Analog | Hypothalamic Neuropeptide / Nonapeptide Hormone | | Primary Receptor Target | GHRH Receptor (GHRHR) | Oxytocin Receptor (OXTR) | | Primary Signaling Pathway | Gs protein-coupled / Adenylyl cyclase / cAMP | Gq/11 protein-coupled / Phospholipase C / IP3-DAG | | Amino Acid Sequence Length | 29 amino acids | 9 amino acids (cyclic disulfide bridge) | | Chemical Formula | C152H252N44O42 | C43H66N12O12S2 | | Molecular Weight | ~3367.2 g/mol | ~1007.2 g/mol | | Reported In Vivo Half-Life | ~30 minutes (rodent models) | ~3 to 5 minutes (plasma) | | Typical Preclinical Models | Murine somatotroph cell culture, Sprague-Dawley tissue repair models | Rodent behavioral assays, smooth muscle contractility in vitro, central cannula microinfusion | | Solvents / Reconstitution | Sterile Bacteriostatic Water, Phosphate-Buffered Saline (PBS) | Sterile Bacteriostatic Water, PBS, Acidified Saline | | Available Unit Sizes | 2mg, 5mg, 10mg lyophilized vials | 2mg, 5mg lyophilized vials |

Understanding these technical distinctions ensures researchers select the correct compound from our comprehensive catalog of research peptides when constructing precise in vitro or animal study models.

CJC-1295 (No DAC) Biochemical Profile & GHRH Receptor Pathways

CJC-1295 without Drug Affinity Complex (DAC), also designated as Modified GRF 1-29, is a synthetic peptide analog of naturally occurring growth hormone-releasing hormone. As a truncated GHRH sequence modified at positions 2, 8, 15, and 27, it exhibits enhanced resistance to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV).

Role: GHRH analog. Studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. Preclinical studies suggest that CJC-1295 (No DAC) binds selectively to the GHRH receptor on anterior pituitary somatotrophs, triggering adenylate cyclase activation and subsequent cyclic adenosine monophosphate (cAMP) accumulation. This cascade stimulates the transcription and exocytosis of growth hormone, maintaining natural physiological pulsatility without total receptor desensitization.

Oxytocin Biochemical Profile & Neuropeptide Receptor Signaling

Oxytocin is a cyclic nonapeptide produced in the paraventricular and supraoptic nuclei of the hypothalamus and secreted by the posterior pituitary. Structurally characterized by a intramolecular disulfide bond between cysteine residues at positions 1 and 6, oxytocin plays a dual role as a circulating neurohormone and a central neurotransmitter.

In vitro data indicate that Oxytocin binds high-affinity Gq/11 protein-coupled oxytocin receptors (OXTR) distributed throughout the central nervous system, myometrial cells, cardiac tissue, and vascular endothelium. Activation of OXTR stimulates phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG). This induces intracellular calcium release from the endoplasmic reticulum, facilitating rapid cellular contractility, gene transcription modification, and synaptic plasticity in experimental setups.

Comparative Pharmacokinetics: Half-Life, Pulse Dynamics, and Bioavailability

The pharmacokinetic behaviors of CJC-1295 (No DAC) and oxytocin diverge sharply due to differences in molecular weight, enzymatic susceptibility, and systemic stability. CJC-1295 (No DAC) was engineered specifically to prolong the biological activity of native GHRH (1-29). Native GHRH has an in vivo half-life of less than 7 minutes in rodent models due to rapid DPP-IV cleavage; modification of the N-terminal amino acids extends the functional half-life of CJC-1295 (No DAC) to approximately 30 minutes.

Conversely, unmodified oxytocin exhibits an extremely short plasma half-life of approximately 3 to 5 minutes in mammalian models, rapidly cleared by renal filtration and enzymatic degradation via oxytocinases (aminopeptidases). Consequently, preclinical protocols studying long-term metabolic or trophic responses frequently favor GHRH analogs like CJC-1295 (No DAC), whereas oxytocin investigations often require continuous intravenous microinfusion, localized central cannulation, or stabilized analog formulations to maintain steady-state receptor engagement.

Preclinical Literature Review: Tissue Repair vs Behavioral & Neuroendocrine Models

Preclinical investigations utilizing CJC-1295 (No DAC) concentrate predominantly on somatic growth pathways, protein synthesis rate, cellular regeneration, and systemic metabolic parameters. In animal models of skeletal muscle trauma, ischemia, and bone defect repair, GHRH stimulation via CJC-1295 (No DAC) has been shown to elevate serum IGF-1 concentrations, accelerating collagen deposition and extracellular matrix remodeling.

In contrast, oxytocin literature revolves primarily around neurobehavioral assays, social bonding parameters, anxiety-like behavioral models, stress response modulation, and smooth muscle physiology. Rodent research demonstrates that central oxytocin administration attenuates the hypothalamic-pituitary-adrenal (HPA) axis response to acute stressors, lowering plasma corticosterone levels and altering amygdalar activity. Additionally, in vitro cardiovascular research examines oxytocin's role in stimulating nitric oxide release from endothelial cells.

Study Design Selection: Determining the Appropriate Research Compound

Selecting between CJC-1295 (No DAC) and oxytocin depends entirely on the primary endpoint of the laboratory investigation. The following criteria clarify which candidate aligns with specific research goals:

Choose CJC-1295 (No DAC) if the research objective involves evaluating GHRH axis activation, GH pulse amplification, systemic IGF-1 upregulation, skeletal muscle protein turnover, fibroblast proliferation, or metabolic rate adjustments in animal models.

Choose Oxytocin if the research design evaluates central neurotransmission, social interaction behaviors, fear extinction, stress-axis dampening, uterine or vascular smooth muscle contraction, or localized OXTR receptor mapping in brain slice cultures.

Combining both compounds in a single experimental design is generally limited to complex multi-axis neuroendocrine studies examining the crosstalk between stress/social signaling and metabolic/growth hormone regulatory mechanisms.

Comparative Class Analysis: GHRH Analogs and Neuropeptides

To properly contextualize CJC-1295 (No DAC), researchers often compare it against other secretagogues and growth factor regulators within the same functional family. For instance, Sermorelin represents the native 29-amino-acid sequence of GHRH without protective substitutions, resulting in a shorter in vivo half-life (~10–12 minutes) than CJC-1295 (No DAC). When evaluating GH pulse generation, scientists frequently pair GHRH analogs with growth hormone secretagogue receptor (GHSR) agonists such as Ipamorelin to observe synergistic amplification of GH release from pituitary somatotrophs.

Understanding these structural and receptor distinctions across our peptides research library allows investigators to build rigorous control groups and cross-compound comparisons, isolating specific receptor kinetics and signaling pathways.

Reconstitution, Storage, and Assay Handling Protocols

Both CJC-1295 (No DAC) and oxytocin are supplied as lyophilized (freeze-dried) powders to ensure chemical stability during transport and storage. Proper laboratory reconstitution protocols are critical to maintain biological activity:

1. Reconstitution: Reconstitute lyophilized vials using Sterile Bacteriostatic Water containing 0.9% benzyl alcohol, or sterile Phosphate-Buffered Saline (PBS, pH 7.4). Utilize our precise reconstitution calculator to determine correct dilution ratios and final concentration per microliter.

2. Solvent Addition: Gently direct the liquid diluent against the glass vial wall rather than directly onto the lyophilized cake to prevent shear stress and peptide denaturation.

3. Dissolution: Gently swirl the vial until complete dissolution is observed. Do not vortex or agitating vigorously.

4. Storage: Reconstituted solutions should be aliquoted into single-use polypropylene microtubes to avoid repeated freeze-thaw cycles and stored at -20°C or -80°C. Unreconstituted lyophilized vials should be kept desiccated at -20°C.

Quality Assurance and Analytical Verification for Laboratory Reagents

Reliable preclinical results demand uncompromising reagent purity and lot-to-lot consistency. PX1 Research manufactures all compounds in state-of-the-art USA-based facilities adhering to strict quality control standards. Every batch undergoes rigorous High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) testing in an ISO 17025 accredited laboratory to verify identity, sequence integrity, and purity exceeding 99%.

Furthermore, our compounds undergo comprehensive endotoxin testing to ensure compliance with strict in vitro and in vivo limits, preventing confounding immune artifacts in cell culture or animal assays. Every shipment includes access to a lot-specific Certificate of Analysis (COA). Laboratories seeking high-volume reagents for extended trial designs can explore our bulk purchasing options through wholesale lab accounts.